UCL Cancer Institute


Experimental Cancer Medicine Centre (ECMC)

The Experimental Cancer Medicine Centre (ECMC) Network is a unique UK-wide initiative jointly funded by Cancer Research UK and the Health Departments of England, Wales, Scotland and Northern Ireland. Providing £70 million of infrastructure support, the Network of 18 centres brings together world-leading scientists and clinicians to drive the discovery, development and testing of new anti-cancer treatments for patients. 


Centre Leads: Professor Tim Meyer and Professor John Hartley
Research Manager and Centre Operations: Dr Mekala Gunaratnam

University College London (UCL) ECMC is committed to performing world-class clinical cancer research to develop new cancer therapies. It does this by conducting early-phase clinical trials that are fully informed by modern molecular and imaging technologies. There is particular expertise and dedicated facilities for trials of antibody-targeted and cellular therapies, biomarker development, medical bioinformatics and cancer genomics.  The Centre supports a dedicated Clinical Research Facility (CRF) based at UCLH where a team of devoted medical staff including oncologists, research nurses and trial coordinators work together on a large portfolio of clinical trials, offering patients access to the latest new drugs. In addition, the Centre provides key infrastructure for laboratories including the GCLP facility and molecular pathology laboratories which support translational cancer research both at UCL and throughout the Network.

Collaborating for patients

The UCL ECMC collaborates with other centres across the ECMC; recruiting to ECMC trials, providing educational meetings and engaging patients and the public in our work. Expertise and resources are thereby deployed to maximum effect for patient benefit.  

Aims of the UCL ECMC

  • Increase the number of early phase clinical trials
  • develop novel methods of delivering and enhancing the outcome from radiotherapy
  • build on our expertise in cellular, gene and immunotherapy to improve the outcome for patients with haematological malignancy and solid tumours
  • identify novel targets and stratify patients for therapy

Treatment modalities

  • Small molecules
  • Biologics
  • Immunotherapy
  • Gene-therapy
  • Radioimmunotherapy
  • Therapeutic vaccines